BR112022022995A2 - Derivados de espiro-sulfonamida como inibidores da proteína de leucemia-1 de células mieloides (mcl-1) - Google Patents

Derivados de espiro-sulfonamida como inibidores da proteína de leucemia-1 de células mieloides (mcl-1)

Info

Publication number
BR112022022995A2
BR112022022995A2 BR112022022995A BR112022022995A BR112022022995A2 BR 112022022995 A2 BR112022022995 A2 BR 112022022995A2 BR 112022022995 A BR112022022995 A BR 112022022995A BR 112022022995 A BR112022022995 A BR 112022022995A BR 112022022995 A2 BR112022022995 A2 BR 112022022995A2
Authority
BR
Brazil
Prior art keywords
mcl
spiro
inhibitors
protein
cell leukemia
Prior art date
Application number
BR112022022995A
Other languages
English (en)
Inventor
Zhuo Jincong
Cao Ganfeng
Paul Combs Andrew
Li Qun
Zhang Huaping
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of BR112022022995A2 publication Critical patent/BR112022022995A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

DERIVADOS DE ESPIRO-SULFONAMIDA COMO INIBIDORES DA PROTEÍNA DE LEUCEMIA-1 DE CÉLULAS MIELOIDES (MCL-1). A divulgação é direcionada às formas cristalinas do composto de Fórmula I: e os sais farmaceuticamente aceitáveis do mesmo. Também são descritas composições farmacêuticas compreendendo compostos de Fórmula I como métodos de uso e preparação.
BR112022022995A 2020-05-13 2021-05-13 Derivados de espiro-sulfonamida como inibidores da proteína de leucemia-1 de células mieloides (mcl-1) BR112022022995A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063024110P 2020-05-13 2020-05-13
PCT/US2021/032263 WO2021231737A1 (en) 2020-05-13 2021-05-13 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein

Publications (1)

Publication Number Publication Date
BR112022022995A2 true BR112022022995A2 (pt) 2023-01-17

Family

ID=76306004

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022995A BR112022022995A2 (pt) 2020-05-13 2021-05-13 Derivados de espiro-sulfonamida como inibidores da proteína de leucemia-1 de células mieloides (mcl-1)

Country Status (11)

Country Link
US (1) US20230357275A1 (pt)
EP (1) EP4149947A1 (pt)
JP (1) JP2023526235A (pt)
KR (1) KR20230024287A (pt)
CN (1) CN115698024A (pt)
AU (1) AU2021271694A1 (pt)
BR (1) BR112022022995A2 (pt)
CA (1) CA3183270A1 (pt)
IL (1) IL298157A (pt)
MX (1) MX2022014219A (pt)
WO (1) WO2021231737A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
CN113166173A (zh) * 2018-11-09 2021-07-23 普莱鲁德疗法有限公司 作为骨髓细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物

Also Published As

Publication number Publication date
KR20230024287A (ko) 2023-02-20
CA3183270A1 (en) 2021-11-18
AU2021271694A1 (en) 2023-01-19
WO2021231737A1 (en) 2021-11-18
IL298157A (en) 2023-01-01
US20230357275A1 (en) 2023-11-09
JP2023526235A (ja) 2023-06-21
MX2022014219A (es) 2023-01-16
CN115698024A (zh) 2023-02-03
EP4149947A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
NI202000078A (es) Compuestos heteroaril tetracíclicos
CR20120628A (es) Morfolinopirimidinas y su uso en terapia
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
BR112023003832A2 (pt) Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
BR112021018950A2 (pt) Compostos de imidazolonilquinolina e seus usos terapêuticos
ECSP22083772A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
CL2022003646A1 (es) Derivados de amidopirimidona
UY39588A (es) Pirazolotiazol carboxamidas y usos de estas como inhibidores de pdgfr
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
MX2021009796A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
CO2024002844A2 (es) Compuestos espirocíclicos
BR112022022995A2 (pt) Derivados de espiro-sulfonamida como inibidores da proteína de leucemia-1 de células mieloides (mcl-1)
CO2023017151A2 (es) Inhibidores de ripk1 de nicotinamida
CU20220023A7 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
BR112022004630A2 (pt) Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
BR112022022367A2 (pt) Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos
EA202192111A1 (ru) Новые тритерпеновые производные в качестве ингибиторов вич
BR112022001067A2 (pt) Inibidores duplos de atm e dna-pk para uso em terapia antitumoral
EA202192051A1 (ru) Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5)